Table 3.

Biological Activity of Human RvWF, LMW-rvWF, and PdvWF in vWF-deficient and Normal Dogs

Dog No.TreatmentDoseHalf-LifeIn Vivo RecoveryMaximum Increase in FVIII ActivityTime to Reach Max. FVIII Activity
vWF:Ag (mg/kg)RCoF (U/kg)vWF:Ag (h)RCoF (h)vWF:Ag (%)RCoF (%)FVIII 2-Stage (%)FVIII 2-Stage (h)
vWF-deficient 
750 rvWF 46 35 22.1 4.7 64 78 173 24 
751 rvWF 92 70 21.6 9.8 70 120 244 48 
 pdvWF 10 63 7.7 NE3-150 33 25 140 48 
754 rvWF 97 75 NE3-151 NE3-151 59 110 226 48 
1140 LMW-rvWF 45 9.0 NE3-150 92 NE3-150 195 48 
Normal 
H9510176 rvWF 45 35 14.5 6.5 33 96 NE NE 
 pdvWF 7.2 32 9.0 3.2 37 59 NE NE 
Dog No.TreatmentDoseHalf-LifeIn Vivo RecoveryMaximum Increase in FVIII ActivityTime to Reach Max. FVIII Activity
vWF:Ag (mg/kg)RCoF (U/kg)vWF:Ag (h)RCoF (h)vWF:Ag (%)RCoF (%)FVIII 2-Stage (%)FVIII 2-Stage (h)
vWF-deficient 
750 rvWF 46 35 22.1 4.7 64 78 173 24 
751 rvWF 92 70 21.6 9.8 70 120 244 48 
 pdvWF 10 63 7.7 NE3-150 33 25 140 48 
754 rvWF 97 75 NE3-151 NE3-151 59 110 226 48 
1140 LMW-rvWF 45 9.0 NE3-150 92 NE3-150 195 48 
Normal 
H9510176 rvWF 45 35 14.5 6.5 33 96 NE NE 
 pdvWF 7.2 32 9.0 3.2 37 59 NE NE 

Abbreviation: NE, not evaluated.

F3-150

Not calculated because some values were below the limit of detection.

F3-151

Treatment of dog no. 754 was on an emergency basis for a nose bleed; blood samples were therefore not taken at all time points.

or Create an Account

Close Modal
Close Modal